As shown in Figure 9D, the most relevant immune inhibitors correlated with the expression of MRPL15 in ovarian cancer were TGF‐β receptor type 1 (TGFβR1; Spearman's rho = −0.284, p = 4.68e‐07), indoleamine 2,3‐dioxygenase 1 (IDO1; Spearman's rho =0.266, p = 2.47e‐06), VTCN1 (Spearman's rho =0.263, p = 3.27e‐06), and CD160 (Spearman's rho = −0.232, p = 4.2e‐05). Here, CD160 is linked to ovarian carcinoma.